UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU

Their core work

Wroclaw Medical University is a Polish medical university specializing in cardiovascular research, clinical trials, and increasingly in medical data science. Their core work spans heart disease treatment — from drug trials (polypills, beta3-adrenergic receptor agonists) to applying big data and machine learning to cardiac medicine. They also contribute to pharmacovigilance in pregnancy, gene therapy for immunodeficiency disorders, and training networks for functional disorders. Their strength lies in bridging clinical cardiology with emerging digital health approaches.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Wroclaw Medical University focused squarely on cardiovascular clinical trials — polypill strategies, beta3-adrenergic receptor agonists, and secondary prevention in elderly patients. From 2019 onward, a clear pivot emerged toward digital health and data-driven medicine: their self-coordinated HEARTBIT_4.0 project applied machine learning and big data analytics to cardiology, while they also moved into personalised health policy (REGIONS4PERMED) and pharmacovigilance data systems (ConcePTION). The trajectory shows a medical school adding computational and data science muscle to its traditional clinical trial expertise.

They are actively building capacity in medical data science and AI applied to cardiology — expect them to seek partners with complementary computational or health informatics expertise.

How they like to work

Wroclaw Medical University predominantly joins consortia as a participant (5 of 7 projects), contributing clinical expertise and patient cohorts rather than leading large collaborative efforts. They coordinated one project (HEARTBIT_4.0), notably in the Widening Participation pillar, suggesting they used that opportunity to build coordination capacity. With 129 unique partners across 25 countries, they have a broad but not deeply repeated network — typical of a mid-sized medical university that joins diverse clinical trial consortia rather than building a fixed circle of collaborators.

They have worked with 129 distinct partners across 25 countries, indicating wide European reach through large clinical trial consortia. Their network is broad rather than deep, spanning Western and Central Europe without a single dominant geographic cluster.

What sets them apart

Wroclaw Medical University sits at the intersection of traditional cardiovascular clinical trials and emerging medical data science — a combination that is still rare among Central European medical schools. Their HEARTBIT_4.0 coordination shows they are actively investing in digital health capacity, making them a strong partner for projects that need both clinical trial infrastructure in Poland and data analytics capabilities. For consortium builders, they offer access to Polish patient populations and clinical networks, combined with growing computational ambitions that align well with the EU's push toward health data spaces.

Highlights from their portfolio

• BETA3_LVH
  Largest single EU grant (EUR 654,585) — a multi-center randomized controlled trial testing a novel beta3-adrenergic receptor agonist for cardiac hypertrophy, representing their most substantial clinical contribution.
• HEARTBIT_4.0
  Their only coordinated project (EUR 275,962), marking a strategic move into medical data science with machine learning and big data applied to heart disease — signals institutional ambition beyond participant roles.
• ETUDE
  Most recent project (2021–2026), a Marie Curie training network on functional disorders, showing expansion beyond cardiology into broader medical training and research capacity building.